Daxxify® is a neuromodulator injectable treatment, similar to Botox, that is developed and manufactured by Revance Therapeutics. It has recently been approved by the US Food and Drug Administration (FDA) for use in the United States.
Daxxify is a purified form of botulinum toxin type A, which is the same active ingredient found in Botox. Botulinum toxin type A is a neurotoxin that temporarily paralyzes the muscles into which it is injected, reducing the appearance of wrinkles and fine lines caused by muscle contractions.
One of the key differences between Daxxify and Botox is the way in which the active ingredient is delivered to the muscle. Daxxify is formulated with Revance’s proprietary TransMTS technology, which allows for a lower dose of the active ingredient to be used while still achieving the same results as traditional botulinum toxin type A treatments. This may result in fewer side effects and a more natural appearance after treatment.
Another difference between Daxxify and Botox is the duration of their effects. Daxxify is designed to last up to six months, while the effects of Botox typically last for three to four months. This means that patients may need fewer treatment sessions with Daxxify.
In addition to its use in treating wrinkles and fine lines, Daxxify is also being studied for the treatment of other conditions such as migraines, hyperhidrosis (excessive sweating), and muscle spasms.
Daxxify is a promising new treatment option for a variety of conditions that can be treated with neuromodulators like Botox. Its unique formulation and delivery method may offer certain benefits over traditional botulinum toxin type A treatments.